To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.
Age 18 years or older.
Diagnosis of CLL/SLL per 2018 iwCLL criteria (See Appendix 1).
Participants with previously treated CLL requiring therapy based on 2018 iwCLL criteria.
The participant is able to take oral medications.
Participants who experienced progression of disease according to 2018 iwCLL criteria while on venetoclax will be excluded.
Patient with prior history of Richter's syndrome or current Richter's Syndrome.
Participants with known hypersensitivity to any of the excipients of pirtobrutinib, venetoclax,obinutuzumab or to any intended study medications.
Known or suspected history of central nervous system (CNS) involvement by CLL/SLL.
Single group
Pirtobrutinib
DrugGiven PO 200mg daily
Venetoclax
DrugGiven PO daily
Obinutuzumab
DrugGiven IV 100mg day 1, 900 mg day 2, 100mg days 8, 15
Safety and adverse events
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5
Click on the lead sponsor to view all of their trials.
M.D. Anderson Cancer Center
Lead sponsor
Eli Lilly and Company
Collaborator
